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Recent declines in adult HIV-1 incidence have followed the large-
scale expansion of antiretroviral therapy and primary HIV prevention
across high-burden communities of sub-Saharan Africa. Mathematical
modeling suggests that HIV risk will decline disproportionately in
younger adult age-groups as interventions scale, concentrating
new HIV infections in those >age 25 over time. Yet, no empirical
data exist to support these projections. We conducted a population-
based cohort study over a 16-y period (2004 to 2019), spanning the
early scale-up of antiretroviral therapy and voluntary medical male
circumcision, to estimate changes in the age distribution of HIV
incidence in a hyperepidemic region of KwaZulu-Natal, South
Africa, where adult HIV incidence has recently declined. Median
age of HIV seroconversion increased by 5.5 y in men and 3.0 y in
women, and the age of peak HIV incidence increased by 5.0 y in
men and 2.0 y in women. Incidence declined disproportionately
among young men (64% in men 15 to 19, 68% in men 20 to 24,
and 46% in men 25 to 29) and young women (44% in women 15 to
19, 24% in women 20 to 24) comparing periods pre- versus post-
universal test and treat. Incidence was stable (<20% change) in
women aged 30 to 39 and men aged 30 to 34. Age shifts in inci-
dence occurred after 2012 and were observed earlier in men than
in women. These results provide direct epidemiological evidence
of the changing demographics of HIV risk in sub-Saharan Africa in
the era of large-scale treatment and prevention. More attention
is needed to address lagging incidence decline among older
individuals.
HIV incidence | age distribution | antiretroviral therapy | HIV prevention
Despite remarkable progress in the expansion and scale-up ofHIV treatment and prevention, 1.7 million new HIV infections
and 770,000 deaths from AIDS-related illnesses occur every year
globally (1). Almost half of new HIV infections and 40% of AIDS-
related deaths are in East and southern Africa. South Africa, with
an adult HIV prevalence of 20%, has the largest HIV epidemic in
the world, with 7.7 million people currently living with HIV (1).
Recent declines in adult HIV-1 incidence across high-burden
communities of sub-Saharan Africa (SSA) are testament to the
success of large-scale combination HIV prevention, including the
expansion of antiretroviral therapy (ART) under universal test and
treat (UTT) and the scale-up of voluntary medical male circumci-
sion (VMMC) (2–5). When implemented at scale, large increases in
viral load suppression from ART expansion are associated with
substantial declines in population-level HIV incidence (2, 3, 5). The
results from four large cluster randomized trials of UTT effective-
ness demonstrated the feasibility of achieving high population ART
coverage and viral load suppression through community mobiliza-
tion (6–9). Yet, the results also showed the challenge of reducing
population-level incidence with treatment alone (10–12).
At the same time that HIV incidence has fallen, the burden of
HIV infection (HIV prevalence) has more than doubled in
those >age 25 (13–17), a result of extended life expectancy among
people living with HIV (PLHIV) on suppressive ART (18, 19).
Mathematical models suggest that new HIV infections will become
increasingly concentrated in older adults over time, a result of
prioritized HIV prevention in youth (20), increasing HIV
prevalence in older adults, and delayed age at infection with
declining risk (12), yet no empirical evidence exists to support
these projections.
Young age is one of the strongest predictors of HIV risk in
SSA, a result of a sexual network structure that places younger
individuals at greater risk of infection from older individuals
(21–23), heterogeneous behavior and biology that increases ex-
posure to and acquisition of HIV in younger women (24–28), and
lower treatment coverage in younger PLHIV (29, 30). Disparities
in HIV risk have supported efforts to target HIV prevention to
younger individuals, especially to women <age 25 (23). As the
epidemic ages, however, older cohorts of HIV-negative individuals
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now face a greater probability of exposure to sexual partners
living with HIV than they did a decade ago (31), albeit with a
reduced viral load because of ART scale-up (13–17, 32, 33).
The expansion of treatment and primary prevention, by low-
ering the overall force of infection (transmission rate), may also
increase the average time to infection, a dynamic observed in
other infectious diseases (34–37). The fewer individuals who
become infected earlier in life means those individuals stay in the
population at risk for longer, thereby shifting the relative share of
infections to older individuals. Age-structured sexual contact pat-
terns specific to sexually transmitted infections can further magnify
age shifts in risk, as individuals tend to mix preferentially with
partners of a similar age-group (21). Older cohorts may thus ac-
count for a growing proportion of HIV incidence as the overall
transmission rate declines in the era of large-scale treatment and
prevention.
Despite enormous progress in efforts to scale-up treatment
and prevention, HIV incidence remains well above epidemic
control thresholds in high-burden communities (2–5, 38). More
will be needed to identify subgroups with elevated risk to guide
regional targets for HIV prevention over the next decade. The
remarkable demographic and geographic heterogeneity charac-
teristic of HIV epidemics across high-burden regions (39, 40) has
ushered in an era of prioritizing the highest risk groups and
geographies to achieve maximum population-level effect (41,
42). Understanding how the demographic landscape of HIV risk
has shifted with the scale-up of combination HIV prevention is
needed to realign prevention targets with current and future
distributions of risk.
Here, we measure nonlinear age- and sex-specific trends in
HIV-1 incidence between 2004 and 2019 from one of the world’s
largest ongoing population-based cohorts in rural KwaZulu-
Natal, South Africa, a region with among the highest HIV inci-
dence rates in the world. Following recent work showing signif-
icant declines in adult HIV incidence in the region (2), we use
statistical approaches that can flexibly reveal a wide range of
HIV incidence patters to test the hypothesis that incidence has
declined differentially by age and gender over a period spanning
the expansion and scale-up of ART and VMMC. We provide
plausible epidemiological explanations for the observed changes
in the age distribution of risk. Our results have major implica-
tions for expanding demographic targets for HIV prevention in
the era of UTT.
Methods
Study Setting. The Africa Health Research Institute (AHRI) surveillance area is
in the Umkhanyakude district of the northern KwaZulu-Natal province, with
a population of ∼100,000 residents and ∼20,000 households (43–45). The
region has among the highest adult HIV prevalence in the world, which has
increased over time from 22% in 2005 to 37% in 2016 (46, 47). Adult (men
15–54 and women 15–49) HIV incidence is also among the highest in the
world (2.3 per 100 person/years (py) in 2017) and has started to decline only
recently (2). ART coverage among PLHIV increased steadily between 2005 to
2017 in men and women, though coverage remains low relative to the
Joint United Nations Program on HIV/AIDS (UNAIDS) 90–90–90 targets
(38.4% among men and 50.6% among women in 2017) (2). UTT was in-
stituted in September of 2016, when ART became available regardless of
CD4+ count (7).
Data Collection. Annual population-based HIV testing is nested within AHRI’s
demographic surveillance system. Since 2003, trained fieldworkers have of-
fered household HIV testing to all eligible participants (aged 15 to 49 y old
among women and 15 to 54 y old among men), with eligibility expanding to
participants 15 y of age and older after 2007. Dried blood spots are prepared
from whole blood for HIV testing according to the UNAIDS’s and World
Table 1. Summary of demographic, behavioral, and HIV-specific
characteristics at last study visit among individuals included in
the population-based incidence cohort (HIV-negative test




Age (years)* 26.36 (9.4)
Age category (%)*
15 to 19 6,141 (27.4)
20 to 24 7,465 (33.3)
25 to 29 3,266 (14.6)
30 to 34 1,377 (6.1)
35 to 39 1,029 (4.6)
40 to 54 3,128 (14.0)
Ever migrated out of the study area 13,502 (60.3)
Ever experienced unemployment† 18,750 (90.5)
Circumcised (ever among men) 3,039 (37.1)
Age at first marriage 26.63 (6.75)
Ever had sex 15,092 (77.2)
Age at first sex (years) 17.23 (2.4)
Lifetime partners (among ever had sex) 2.68 (3.2)
ART uptake (ever on ART among HIV+) 1186 (33.2)
All percentages are reported out of nonmissing responses.
*Age is calculated as the mean over follow-up.
†Unemployment data unavailable for 2019.
Fig. 1. Crude number of HIV seroconversions, py, and incidence rates observed by continuous age and year stratified on sex and averaged across 300 datasets
with seroconversion randomly imputed between the last negative and first positive. The numbers are rounded to the zero-decimal place for py and sero-
conversions. Incidence rates over 100 per 100 py were observed in age-year bins where at least one seroconversion occurred in less than 1 py.
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Health Organization’s Guidelines for Using HIV Testing Technologies in
Surveillance (48). HIV serostatus was determined by antibody testing with a
broad-based HIV-1/HIV-2 enzyme-linked immunosorbent assay (ELISA) fol-
lowed by a confirmatory ELISA (44).
Demographic and general health data are collected annually during
household visits to record information on in and out migration, occupation,
marital status, and sexual health, including number of lifetime sex partners
and age at sexual debut. Self-reported circumcision status has been collected
since 2009, when the local VMMC program started.
Incidence Measurement. HIV incidence was measured by directly observed
changes in HIV serostatus among study participants (men aged 15 to 54 y old
and women aged 15 to 49 y old) who tested HIV negative followed by at least
one subsequent valid HIV test result. This method represents the gold standard
for directly estimating incidence in a population cohort. Due to periodic testing,
we did not observe the exact date of seroconversion for participants with an
HIV-positive test result. We randomly imputed a seroconversion date between
the last negative and first positive test dates under a constant hazard as-
sumption (49). We then right-censored person time at the imputed serocon-
version date or at the latest HIV-negative test date if the repeat tester did not
seroconvert during the observation period. To account for the uncertainty of
the single random-point method, we repeated this procedure to generate 300
imputed datasets for model fitting.
Statistical Analysis. Person-time incidence rates and 95% CIs were estimated by
continuous age and year for men and women separately from fitted Poisson
generalized additive models (GAMs) with a nonlinear interaction between
study year (2004 to 2019) and age using penalized thin-plate regression splines
(50) (SI Appendix). The models were estimated for each of 300 imputed
datasets and point estimates and standard errors were combined using Rubin’s
rules (51). The fitted models were used to estimate the smoothed age distri-
bution of incidence per 100 py by sex and year. The age of peak HIV incidence
was calculated as the age of maximum incidence for each year from the fitted
model. The area under the curve was used to estimate the proportion of the
incidence age distribution <age 25 by year. This metric estimates the pro-
portion of new infections in individuals under 25 that would arise in a pop-
ulation at risk with a constant age distribution. Circumcision prevalence by
continuous age and calendar year (2009 to 2019) was estimated among HIV-
negative men included in the longitudinal cohort using smoothed GAMs
with a logistic link and a nonlinear interaction term between age and year
with smoothing using penalized thin-plate regression splines.
Poisson generalized linear models (GLMs) were used to estimate incidence
rate ratios (IRR) and 95% CIs by categorical age-groups (15 to 19, 20 to 24, 25 to
29, 30 to 34, and 35 to 39, 40+) and categorical year corresponding to dates
before and after UTT went into effect in 2016. Models for men were addi-
tionally run, adjusting for individual-level circumcision status to assess age shifts
beyond those explained by differential VMMC uptake by age over time. To
ensure that the results were robust to incomplete participation in the HIV
testing of the underlying study population, Poisson GLMs were additionally run
including inverse probability weights (IPWs) to account for missingness at ran-
dom following methods used in previous cohort studies of HIV incidence (2, 3).
IPWs were estimated from a logistic regression model with a probability of
nonparticipation regressed on the following covariates: continuous age, num-
ber of migration events outside the study area that resulted in a temporary
change of residence, length of time spent outside the study area during
migration events, and HIV prevalence in the surrounding community
by year.
Ethical Approval. All participants provided written informed consent prior to
the household-based interview and collection of dried blood spots for HIV
testing. The biomedical and ethics committee (BREC) of the University of
KwaZulu-Natal, Durban, South Africa, provided ethics approval for data
collection and use (BREC approval number BE290/16).
Results
The longitudinal HIV incidence cohort included 22,406 individ-
uals who tested HIV negative followed by at least one other test
between 2004 to 2019. The cohort was young (27.4% aged 15 to
19 y old and 33.3% aged 20 to 24 y old), mobile (60.3% had ever
spent time away from the study area and 84% of moves out of the
study area were followed by a subsequent return), and experienced
high levels of unemployment (90.5% ever experienced unem-
ployment) (Table 1). The self-reported circumcision prevalence
among men (ever circumcised) was 37.1% by the end of the study,
increased over time between 2009 to 2019, and was higher among
younger men (64.7% in men 20 y of age and 38.5% among men
35 y of age in 2019) (SI Appendix). ART initiation (ever-initiated
ART) among PLHIV in the incidence cohort was low (33.2%)
based on linked clinical records. The age at first marriage was 26.6
y, and 77.2% reported having had initiated sex; the average age of
sexual debut (among those initiating first sex) was 17.2 y, and the
mean number of reported lifetime sexual partners (among those
who reported any lifetime partners) was 2.7. A summary of de-
mographic characteristics comparing those included versus not
included in the incidence cohort can be found in SI Appendix.
Between 2004 and 2019, 3,574 new HIV infections were ob-
served (887 among men and 2,687 among women) in 103,775 py
of follow-up (43,629 py among men and 60,146 py among
women) for an overall incidence rate of 3.4 per 100 py (2.0 per
100 py in men aged 15 to 54 y old and 4.5 per 100 py in women
aged 15 to 49 y old). The median (interquartile range, IQR) time
between last negative and first positive test among those who
seroconverted was 3.0 y (IQR = 1.4 to 5.8 y) (SI Appendix). The
py of follow-up and number of HIV seroconversions were con-
centrated in men and women <age 25, reflecting the young av-
erage age of the cohort (Fig. 1).
The age distribution of HIV incidence in men and women
remained stable throughout the earlier half of the study period
(2004 to 2012) and shifted older in the latter half of follow-up
Fig. 2. Year-specific cross-sections of incidence age distributions and 95%
CIs from years 2004, 2012, and 2019. The largest difference in age distribu-
tion occurred in the latter half of the study period, between 2012 and 2019.
Fig. 3. Smoothed age- and year-specific relative risks comparing age-
specific incidence by year to age-specific incidence in 2004 (reference year).
Akullian et al. PNAS | 3 of 8






























(2012 to 2019) (Fig. 2 and see SI Appendix for all year-specific
age distributions of incidence). HIV incidence declined (relative
to 2004) first in the youngest men and women, with some evi-
dence of early declines also observed in the oldest age-groups
(Fig. 3). Incidence in women 25 to 34 y of age stayed relatively
constant (with some indication of increase between 2008 to
2016) and declined the least of any age/sex subgroup (by <20%
comparing 2019 levels to 2004 levels) (Fig. 3). Shifts in the in-
cidence age distribution were the result of substantial declines in
incidence (>50%) in men <age 30 and moderate declines in
incidence (20 to 40%) in women <age 25.
The median age of seroconversion increased over the study
period by 5.5 y in men (by 7.5 y from its low in 2006), from age
25.5 (IQR, 21.0 to 31.0) in 2004 to age 31.0 (IQR, 27.5 to 34.0) in
2019, and by 3.0 y in women, from its low at age 21.0 (IQR, 18.0
to 29.5) in 2004 to 24.0 (IQR, 20.0 to 27.0) in 2019 (Fig. 4A). The
median age of the underlying HIV negative cohort increased by
3.0 y in men and 4.0 y in women. The age with the highest in-
cidence (i.e., age of peak incidence) shifted older by 5 y in men
between 2012 to 2019 (from age 26 to 31 y old) with no sub-
stantial change prior to 2012 (Fig. 4B). In women, the age of
peak incidence increased by 2 y over the study period (age 22 y in
2004, 23 y in 2012, and 24 y in 2019). The highest age-specific
incidence in men declined steadily from 5.0 per 100 py in 2004 to
2.0 per 100 py in 2019, with the steepest declines occurring after
2012. In women, the highest age-specific incidence initially rose
from 6.3 per 100 py in 2004 to 7.3 per 100 py in 2012 after which
it declined to its lowest level of 4.4 per 100 py in 2019 (Fig. 4C).
The proportion of the incidence age distribution <age 25
(calculated as the area under the age-incidence curve) declined
in men from its max of 20.0% in 2009 to 10.2% in 2019 and
declined in women from a max of 42.2% in 2009 to 36.2% in
2019 (Fig. 4D).
In analyses using categorical age (5-y bins) comparing the pe-
riods before and after UTT went into effect in 2016, the age of
peak incidence in men shifted from age 25 to 29 y, incidence rate
(IR) = 3.9, 95% CI (3.3 to 4.6) to age 30 to 34 y, IR = 2.8, 95% CI
(1.7 to 4.6). The peak incidence in women remained constant at 20
to 24 y in both the pre-UTT, IR = 6.7, 95% CI (6.3 to 7.2) and
post-UTT eras, IR = 5.1, 95% CI (4.3 to 6.4) (Fig. 5, numerical
values in Table 2). Incidence declined to the largest extent in young
men and women comparing the periods before and after UTT
went into effect in 2016. Incidence declined by 64.4% (IRR = 0.36,
95% CI, 0.15 to 0.82) in men aged 15 to 19 y, 68.1% (IRR = 0.32,
95% CI, 0.18 to 0.59) in men aged 20 to 24 y, and 45.8% (IRR =
0.54, 95% CI, 0.31 to 0.94) in men 25 to 29 and declined by 43.5%
(IRR = 0.56, 95% CI, 0.43 to 0.73) in women aged 15 to 19 y,
24.0% (IRR = 0.76, 95% CI, 0.62 to 0.96) in women aged 20 to 24
y, and 24.0% (IRR = 0.76, 95% CI, 0.56 to 1.02) in women aged 25
to 29 y. (Fig. 5, numerical values in Table 2). In models adjusted for
male circumcision status, incidence similarly declined to the largest
extent in young men; there was a 56.8% decline (IRR = 0.43, 95%
CI, 0.21 to 0.95) in men 15 to 19 y of age and a 61.6% decline
(IRR = 0.38, 95% CI, 0.22 to 0.67) in men 20 to 24 y of age, with
no significant evidence of decline in men >age 25 (Table 2). Age-
specific incidence rates comparing pre- to post-UTT were also
similar in models including inverse probability survey weights to
account for potential selection bias attributed to differential
Fig. 4. Annual sex-specific trends in (A) median age at seroconversion, (B) age of peak incidence, (C) peak age-specific HIV incidence (per 100 py), and (D)
proportion of the incidence age distribution under age 25. (B–D) Derived from modeled age-specific HIV incidence; A is calculated as the median age at
seroconversion across n = 300 imputed datasets.
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probabilities of repeat testing by age, migration status, and
community-level HIV prevalence (SI Appendix).
Discussion
We observed a marked age shift in the distribution of HIV-1
incidence between 2004 and 2019 in one of the world’s largest
population-based HIV cohorts in rural KwaZulu-Natal, South
Africa. HIV incidence shifted to older age-groups because inci-
dence declines were large among both young men (<age 30) and
young women (<age 25) and small among older adults. Age
shifts in male incidence occurred earlier and were larger than
those in women. This finding likely reflects a delay in the indirect
protection afforded to the female partners of lower-incidence
young men as they age (52, 53). Our results provide direct epi-
demiological evidence of the changing demographics of HIV risk
in SSA in the era of large-scale HIV treatment and prevention
and highlight the need to re-evaluate age targets for intervention
strategies going forward.
Several HIV-specific epidemic dynamics may explain the ob-
served age shifts in HIV incidence. First, age-specific targeting of
primary prevention, including the scale-up of VMMC over the past
decade, has likely played a role in reducing HIV risk dispropor-
tionately in younger male cohorts and, to some extent, in the young
female partners of those men as they age. In our analysis, the
prevalence of male circumcision increased to the largest extent
among young men (though men >25 y of age also experienced
moderate increases in coverage). However, when adjusting models
for circumcision status, we observed a similar pattern as in unad-
justed models: larger incidence declines in young men (<25) com-
pared to older men, indicating that differential VMMC targeting
and uptake in younger men is not the primary factor driving age
shifts in risk.
Second, uneven changes in age-specific population viremia over
time may have shifted the age distribution of risk older. HIV in-
cidence is inextricably linked to the population prevalence of de-
tectable viral load, a population-level biomarker that combines the
prevalence of HIV and detectable viral load among PLHIV to
estimate the background risk of HIV acquisition (32, 54). While
older age-groups tend to have the highest ART coverage (2, 3, 55),
the prevalence of HIV infection in SSA has more than doubled in
those >age 25 in the past two decades (13, 14, 21, 29), a result of
both the natural aging of high incidence cohorts and the increase
in life expectancy of PLHIV on suppressive ART (17–19, 56, 57).
The counteracting effects of decreasing viral load among PLHIV
and increasing HIV prevalence of aging cohorts results in persis-
tently elevated prevalence of detectable viremia in some older
age-groups (5, 29, 58, 59). In our study, despite the expanding
coverage of ART and VMMC, men and women in the 25- to 34-y
age-group experienced minimal changes in incidence over time.
Stable incidence in this group may reflect constant population
prevalence of detectable viral load in the corresponding age-
groups of their partners. In contrast, younger cohorts benefit
from both the direct effects of increasing ART coverage and the
indirect effects of immediate reductions in prevalence from de-
clining incidence. Thus, even modest increases in ART coverage
can produce disproportionately larger declines in incidence in
younger age-groups. Additionally, though not significant, we did
observe some evidence of declines in incidence in the oldest
women (40 to 49 y of age) and men (40 to 54 y of age), which may
reflect larger increases in ART coverage in the oldest age-groups
Fig. 5. (Top) Fitted age distribution of HIV incidence for pre-UTT (2004 to 2015) and post-UTT (2016 to 2019). (Bottom) Categorical, age-specific IRRs
comparing incidence post-UTT (2016 to 2019) to incidence pre-UTT (2004 to 2015).
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compared to those 25 to 39 y of age. Further study can confirm
this hypothesis by testing for differential changes in population
viremia over time by age and sex.
Third, declines in the overall HIV transmission rate may further
delay the time to infection, shifting the distribution of new infec-
tions to older. The inverse relationship between the force of in-
fection and age at infection has been observed across infectious
disease systems in which early exposure and immunity provide
some degree of subsequent protection (35, 36). For life-long dis-
eases like HIV, a reduced force of infection can shift the distri-
bution of risk older by changing the risk profile of population
cohorts as they age. Under a lower force of infection, individuals
with greater biological and behavioral susceptibility to HIV remain
in the population at risk for a longer time (60), thereby increasing
the susceptibility profile of the older population at risk compared
to earlier birth cohorts. Additional study is needed to test this
hypothesis over longer time periods. Dynamic changes in the age
distribution of risk must further be evaluated against demographic
shifts in SSA’s age structure, which is expected to become younger
over time. Thus, even as overall HIV risk declines, the absolute
number of new infections among youth may increase (61).
Age shifts in HIV incidence in high-burden communities have
major implications for realigning demographic targets for preven-
tion to include older age-groups. While the continued focus of HIV
prevention on younger populations, especially adolescent girls and
young women, remains a crucial component of population-level
risk reduction (62, 63), more attention is needed to address lag-
ging incidence declines among older individuals. Expanding age
targets for ongoing prevention programs (including pre-exposure
prophylaxis and VMMC) may be necessary to address a changing
demographic landscape of risk in SSA over the coming decade.
HIV prevention methods with limited effectiveness in younger age-
groups may prove effective in older age-groups because of better
uptake, adherence, and product efficacy (64, 65) and could be
reconsidered as effective preventive modalities with expanded age
targeting.
Our study’s strengths include the use of one of the world’s
largest population-based HIV cohort to estimate incidence—the
gold standard approach to directly measure changes in population-
level incidence—over a 16-y period spanning the scale-up of ART
and VMMC. We employed flexible models to capture nonlinear
trends in age- and sex-specific incidence and quantify changes in
the age distribution of risk over time. Nonresponse or refusal to
participate in annual HIV testing is common in the AHRI sur-
veillance area (ranging from 34 to 60%; SI Appendix) (13, 46),
similar to that in other regions in South Africa (66). We con-
ducted further sensitivity analysis to ensure our results were ro-
bust to differences in testing participation over time. We found
no differences in age- and gender-specific incidence rates
(comparing pre- to post-UTT era) in analyses weighted for fac-
tors associated with HIV testing probability that may have biased
the primary results. We further incorporated uncertainty in se-
roconversion date (between last negative and first positive for
those who seroconverted) into our estimates using the random-
point imputation method for interval censored data, which has
been shown to be robust to bias when data contain long cen-
soring intervals and suboptimal testing rates (49).
The limitations of our study include the inability to account for
differences in unmeasured behavioral factors over time that
could account for some of the age-specific incidence trends.
Table 2. Age-, sex-, and male circumcision status–specific incidence rates per 100 py and IRRs
comparing the periods before (2004 to 2015) and after (2016 to 2019) UTT went into effect
Sex Age-group
Incidence rate (per 100 py)
IRR2004 to 2015 2016 to 2019
Women 15 to 19 5.32 (4.87 to 5.79) 3.00 (2.33 to 3.77) 0.56 (0.43 to 0.73)
20 to 24 6.73 (6.27 to 7.20) 5.12 (4.25 to 6.37) 0.76 (0.62 to 0.96)
25 to 29 5.96 (5.37 to 6.65) 4.53 (3.52 to 5.88) 0.76 (0.56 to 1.02)
30 to 34 4.17 (3.50 to 4.99) 4.01 (2.78 to 5.66) 0.96 (0.64 to 1.42)
35 to 39 1.94 (1.50 to 2.47) 1.74 (0.95 to 3.09) 0.89 (0.46 to 1.71)
40 to 49 1.55 (1.32 to 1.83) 1.00 (0.59 to 1.73) 0.64 (0.36 to 1.15)
Men 15 to 19 0.92 (0.72 to 1.16) 0.32 (0.14 to 0.71) 0.36 (0.15 to 0.82)
20 to 24 2.74 (2.40 to 3.13) 0.87 (0.51 to 1.53) 0.32 (0.18 to 0.59)
25 to 29 3.91 (3.32 to 4.55) 2.13 (1.24 to 3.64) 0.54 (0.31 to 0.94)
30 to 34 3.26 (2.59 to 4.12) 2.78 (1.68 to 4.57) 0.85 (0.49 to 1.46)
35 to 39 2.62 (1.87 to 3.60) 1.71 (0.65 to 4.24) 0.66 (0.22 to 1.71)
40 to 54 1.43 (1.12 to 1.80) 0.86 (0.00-Inf) 0.68 (0.00-Inf)
Men (circumcised)* 15 to 19 0.52 (0.35 to 0.76) 0.22 (0.11 to 0.48) 0.43 (0.21 to 0.95)
20 to 24 1.58 (1.12 to 2.24) 0.60 (0.33 to 1.06) 0.38 (0.22 to 0.67)
25 to 29 2.24 (1.52 to 3.24) 1.38 (0.76 to 2.41) 0.62 (0.36 to 1.09)
30 to 34 1.89 (1.26 to 2.84) 1.74 (0.99 to 3.08) 0.92 (0.54 to 1.56)
35 to 39 1.50 (0.94 to 2.37) 1.11 (0.41 to 2.94) 0.75 (0.27 to 2.06)
40 to 54 0.82 (0.53 to 1.20) 0.18 (0.00-Inf) 0.21 (0.00-Inf)
Men (uncircumcised)* 15 to 19 0.93 (0.74 to 1.18) 0.40 (0.19 to 0.84)
20 to 24 2.82 (2.48 to 3.21) 1.08 (0.63 to 1.84)
25 to 29 4.02 (3.38 to 4.69) 2.46 (1.49 to 4.20)
30 to 34 3.37 (2.64 to 4.32) 3.06 (1.99 to 5.04)
35 to 39 2.68 (1.96 to 3.66) 1.98 (0.78 to 5.20)
40 to 54 1.44 (1.13 to 1.84) 0.30 (0.00-Inf)
IRR = incidence rate ratio comparing age-specific incidence in the UTT era (2016 to 2019) relative to age-
specific incidence in the pre-UTT era (2004 to 2015). Bold IRRs indicate significance at alpha < 0.05.
*Incidence rates for circumcised and uncircumcised men are estimated by fitting a generalized linear model with
an indicator for individual-level circumcision status (circumcision model). Fitted IRR’s from the circumcision model
are adjusted for circumcision status without an interaction term and so are equivalent for both uncircumcised
and circumcised men.
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Disproportionate changes in sexual risk behavior in younger
compared to older age-groups may account for some of the
observed age shifts in risk. However, some indicators suggest that
sexual risk behavior has not changed substantially over the
course of the study period. Self-reported condom use has
remained relatively stable in the cohort since 2012 (2), consistent
with a lack of change in condom use in a nearby cohort (67).
Further study is needed to quantify the relative contributions of
changes in age-specific sexual behaviors (including changes in
age of sexual debut, frequency of partnership turnover, and age
of sexual partners) in addition to the effects of biomedical
interventions.
Aging cohorts are expected to comprise an increasingly larger
proportion of the population living with HIV across SSA in the
UTT era (68–71), prompting research and programmatic efforts
to address the public health challenges of an aging population
living with HIV (57, 72–74). Strategies specifically tailored to
older adults, and especially to older women (75), may be needed
to bring incidence below epidemic control levels.
In conclusion, the age distribution of HIV incidence has
shifted older in a high-burden community of South Africa,
contemporaneous with the large-scale expansion of HIV treat-
ment and prevention over the last decade. We hypothesize that
age-specific disparities in treatment coverage and primary HIV
prevention targeting, increasing prevalence of HIV in older age-
groups, and delayed age at infection contribute to age shifts in
HIV risk. The changing demographics of the HIV epidemic in
high-burden communities have implications for the design of
interventions and may require expanding the scope of HIV
prevention to include older age-groups (those >25) in the era of
UTT, who will likely comprise a larger proportion of incidence as
the HIV epidemic continues to contract.
Data Availability. The datasets used in this study have been de-
posited in the AHRI data repository (https://data.ahri.org/index.
php/home). To access the licensed datasets, the applicant must
agree to the terms and conditions of use by completing an Ap-
plication for Access to a Licensed Dataset. This request will be
reviewed by the AHRI Data Release Committee, who may decide
to approve the request, to deny access to the data, or to request
additional information from the applicant.
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